Immunicum publishes supplement to prospectus for rights issue

Gothenburg, Sweden, 2014-05-26 12:24 CEST (GLOBE NEWSWIRE) — Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this press release would be unlawful.

Immunicum AB (publ) (“Immunicum”) has today published a supplement to the prospectus dated May 12, 2014 prepared in connection with the ongoing rights issue. The supplement to the prospectus follows from the press release “IMMUNICUM REPORTS PRELIMINARY REGRESSION DATA AFTER ADD-ON THERAPY WITH TYROSINE KINASE INHIBITORS AND CONTINUED COMPELLING SURVIVAL DATA FROM THE FORMALLY COMPLETED PHASE I/II-STUDY IN RENAL CELL CARCINOMA” published on May 21, 2014.

The supplement to the prospectus is a part of, and should be read together with, the prospectus. The supplement and the prospectus have been approved by and registered with the Swedish Financial Supervisory Authority and are available on Immunicum’s website www.immunicum.seand on Pareto Securities’ website

Irrespective of the supplement to the prospectus, the timetable is expected remain as set out in the prospectus. The last day to subscribe for shares is thus 28 May 2014.

Investors who, prior to the publication of the supplement to the prospectus, have applied for or otherwise consented to subscription for the securities covered by the prospectus, have the right to withdraw their application or consent to subscribe, within two working days of the publication of the prospectus supplement.

If an investor wants to exercise the right of withdrawal, the investor must inform the bank or nominee which received the application about the withdrawal at the latest on 28 May 2014. A withdrawal of an application to subscribe for shares must be made in relation to all shares applied for by the investor. If an investor exercises its right of withdrawal any payment for shares will be repaid as soon as possible. No interest will be paid on the repayment amount.

An application which is not withdrawn will remain binding and those investors who wish to remain as subscribers do not need to take any further action.

Pareto Securities AB is financial adviser to Immunicum.


For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, +46 31 41 50 53,


About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum’s products can be produced in large scale. The vaccines are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.

Redeye AB is chosen as Immunicum’s Certified Adviser.

Tel: 08-545 013 31.


Important notice

The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, New Zeeland, Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa. The distribution of this press release in certain other jurisdictions may be restricted. The information in this press release shall not constitute an offer to sell or the solicitation of an offer to purchase any securities in Immunicum in any jurisdiction. This press release does not constitute, or form part of, an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Immunicum does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being distributed or sent and may not be distributed or sent to the United States, Australia, New Zeeland, Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa.

This document has not been approved by any regulatory authority. This document is a press release and not a prospectus and investors should not subscribe for, or purchase any securities referred to in this document, except on the basis of information in the prospectus (including supplements thereto) which has been published by Immunicum and is available, inter alia, on its web site.

European Economic Area

Immunicum has not resolved to offer to the public shares or rights in any Member State of the European Economic Area other than Sweden and any other jurisdiction into which the offering of shares or rights may be passported. Within such Member States of the European Economic Area other than Sweden (and any other jurisdiction into which the offering of shares or rights may be passported) and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken as of this date to make an offer to the public of shares or rights requiring a publication of a prospectus in any Relevant Member State. As a result hereof, the shares or rights may only be offered in Relevant Member States: (a) to a qualified investor (as defined in the Prospectus Directive or under applicable law); or (b) in any other respect that does not require that Immunicum publishes a prospectus in accordance with Article 3(2) of the Prospectus Directive.

For the purposes hereof, the expression an “offer to the public of shares or rights” in any Relevant Member State means the communication, in any form, of sufficient information on the terms of the offer and the shares or rights to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in a Relevant Member State due to the implementation of the Prospectus Directive in that Member State and the expression “Prospectus Directive” means Directive 2003/71/EC including any relevant implementing measure in each Relevant Member State.

Pareto Securities AB is acting for Immunicum and no one else in connection with the Rights Issue and will not be responsible to anyone other than Immunicum for providing the protections afforded to its clients or for providing advice in relation to the Rights Issue and/or any other matter referred to in this announcement.

Pareto Securities AB accepts no responsibility whatsoever and makes no representation or warranty, express or implied, for the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by Pareto Securities AB, or on its behalf, in connection with Immunicum and the new shares, the Rights Issue, and nothing in this announcement is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or future. Pareto Securities AB accordingly disclaims to the fullest extent permitted by law all responsibility and liability whether relating to damages, contract or otherwise which it might otherwise have in respect of this announcement or any such statement.

Forward-looking statements

This press release contains forward-looking statements that reflect the company’s current views with respect to future events and potential financial performance. Although Immunicum believes that the expectations reflected in such statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results can differ materially from those set out in the forward-looking statements as a result of various factors. You are advised to read this announcement, and the prospectus (and supplements thereto) and the information incorporated by reference therein, in their entirety for a further discussion of the factors that could affect the Immunicum’s future performance and the industries in which Immunicum operates. In light of these risks, uncertainties and assumptions, it is possible that the events described in the forward-looking statements in this announcement may not occur.

Keep reading

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell …